Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma

被引:7
|
作者
Ohno, Takashi [1 ,2 ]
Kubouchi, Yasuaki [1 ,2 ]
Wakahara, Makoto [1 ,2 ]
Nosaka, Kanae [1 ]
Sakabe, Tomohiko [1 ]
Haruki, Tomohiro [2 ]
Miwa, Ken [2 ]
Taniguchi, Yuji [2 ]
Nakamura, Hiroshige [2 ]
Umekita, Yoshihisa [1 ]
机构
[1] Tottori Univ, Fac Med, Dept Pathol, Div Organ Pathol, 86 Nishicho, Yonago, Tottori 6838503, Japan
[2] Tottori Univ, Fac Med, Dept Surg, Div Gen Thorac Surg, Tottori, Japan
关键词
Maspin; adenocarcinoma; immunohistochemistry; PULMONARY ADENOCARCINOMA; NUCLEAR-LOCALIZATION; PROGNOSTIC VALUE; CANCER; EXPRESSION; CLASSIFICATION; RECURRENCE; SURVIVAL; PREDICTOR; FEATURES;
D O I
10.21873/anticanres.12553
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Maspin is a tumor-suppressor protein and its prognostic value in lung adenocarcinoma has been reported. However, little is known about the clinical impact of subcellular localization of maspin in early-stage lung adenocarcinoma. We aimed to evaluate the clinical significance of subcellular localization of maspin in patients with pathological stage (p-stage) IA lung adenocarcinoma categorized by the new eighth edition TNM classification. Patients and Methods: We immunohistochemically analyzed 181 tissue samples from p-stage IA1 (n=37), IA2 (n=92) and IA3 (n=52) lung adenocarcinomas using antibody for maspin. Results: The 181 cases fell into five predominant subtypes: lepidic (n=32), acinar (n=97), papillary (n=30), solid (n=20) and micropapillary (n=2). The frequencies of maspin staining were: cytoplasmic-only in 24.9%; pancellular (nuclear and cytoplasmic) in 8.8%; nuclear-only in 0.6%; no staining in 65.7%. Cytoplasmic-only staining significantly correlated with high pathological T-classification (p=0.039), lymphatic invasion (p=0.002) and poorer tumor differentiation (p=0.002). The patients were followed-up for 12-151 months (median=74 months), and the cytoplasmic-only staining significantly correlated with shorter disease-free survival (DFS) (p=0.034) and disease-specific survival (DSS) (p=0.036) by log-rank tests. In Cox's multivariate analysis, lymphatic invasion had the most significant effect on shorter DFS and DSS. Conclusion: The expression of maspin in the cytoplasm alone could be useful for predicting unfavorable prognoses in patients with p-stage IA lung adenocarcinoma.
引用
收藏
页码:3001 / 3007
页数:7
相关论文
共 50 条
  • [1] Clinical Significance of Subcellular Localization of Maspin in Patients with Pathological Stage IA Lung Adenocarcinoma
    Ohno, T.
    Nosaka, Y.
    Fujiwara, W.
    Miyamoto, T.
    Kadonaga, T.
    Kidokoro, Y.
    Wakahara, M.
    Takagi, Y.
    Tanaka, Y.
    Haruki, T.
    Miwa, K.
    Suzuki, Y.
    Taniguchi, Y.
    Nakamura, H.
    Umekita, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S770 - S771
  • [2] Clinical significance of the combination of preoperative SUVmax and CEA in patients with clinical stage IA lung adenocarcinoma
    Hashinokuchi, Asato
    Haratake, Naoki
    Takenaka, Tomoyoshi
    Matsudo, Kyoto
    Nagano, Taichi
    Watanabe, Kenji
    Kosai, Keisuke
    Oku, Yuka
    Ono, Yuki
    Takamori, Shinkichi
    Kohno, Mikihiro
    Baba, Shingo
    Ishigami, Kousei
    Yoshizumi, Tomoharu
    THORACIC CANCER, 2022, 13 (18) : 2624 - 2632
  • [3] Relationship Between EGFR Mutation and Pathological Differentiation in Patients with Clinical Stage IA Lung Adenocarcinoma
    Osawa, J.
    Shimada, Y.
    Maehara, S.
    Masaru, H.
    Kakihana, M.
    Kajiwara, N.
    Ohira, T.
    Ikeda, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S900 - S900
  • [4] Clinical Significance of the Presence of MECA-79-Positive Tumor Cells in Pathological Stage IA Invasive Adenocarcinoma of the Lung
    Saito, T.
    Ishida, M.
    Akama, T.
    Suzuki, M.
    Hanaoka, H.
    Takahashi, H.
    Maru, N.
    Utsumi, T.
    Matsui, H.
    Taniguchi, Y.
    Hino, H.
    Murakawa, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S503 - S503
  • [5] Predicting pathological lymph node status in clinical stage IA peripheral lung adenocarcinoma
    Aokage, Keiju
    Suzuki, Kenji
    Wakabayashi, Masashi
    Mizutani, Tomonori
    Hattori, Aritoshi
    Fukuda, Haruhiko
    Watanabe, Shun-Ichi
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2021, 60 (01) : 64 - 71
  • [6] Lymphatic permeation status stratifies the prognosis of pathological node positive patients with clinical stage IA lung adenocarcinoma
    Mimae, T.
    Tsutani, Y.
    Miyata, Y.
    Yoshiya, T.
    Ibuki, Y.
    Nakayama, H.
    Okumura, S.
    Yoshimura, M.
    Okada, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S810 - S810
  • [7] Prognostic Nomograms Based on Ground Glass Opacity and Subtype of Lung Adenocarcinoma for Patients with Pathological Stage IA Lung Adenocarcinoma
    Zhai, Wenyu
    Liang, Dachuan
    Duan, Fangfang
    Wong, Wingshing
    Yan, Qihang
    Gong, Li
    Lai, Renchun
    Dai, Shuqin
    Long, Hao
    Wang, Junye
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [8] RECURRENCE RISK FACTORS FOCUSED ON CLINICAL, RADIOLOGICAL AND PATHOLOGICAL FEATURES IN RESECTED STAGE IA ADENOCARCINOMA OF THE LUNG
    Yang, Hee Chul
    Park, Eoksung
    Lee, Jung-Moon
    Sim, Eunee
    Sung, S-W
    Jheon, Sanghoon
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S500 - S501
  • [9] Prognostic significance of micropapillary and solid patterns in stage IA lung adenocarcinoma
    Peng, Bin
    Li, Guofeng
    Guo, Yanhua
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (09): : 10562 - 10569
  • [10] Prognostic impact of noninvasive areas in resected pathological stage IA lung adenocarcinoma
    Kinoshita, Fumihiko
    Shimokawa, Mototsugu
    Takenaka, Tomoyoshi
    Okamoto, Tatsuro
    Taguchi, Kenichi
    Oda, Yoshinao
    Yoshizumi, Tomoharu
    THORACIC CANCER, 2023, 14 (18) : 1651 - 1659